The immune system produces a huge variety – hundreds of billions – of high-affinity antibodies. Immunologists have been asking how B cells accomplish this for decades, and in the past five years, the ...

with a coverage of up to 10 1 native antibody fragments (next-generation-sequencing-verified diversity). By performing the whole antibody-discovery process in vitro and bypassing animal ...

Existing monoclonal antibody development technologies, such as hybridoma technology, suffer from a loss of diversity due to cell fusion efficiency, and phage display technology creates antibodies ...

Ligand uses Carterra’s LSA to validate new strains of transgenic animals, such as transgenic chickens, to confirm that the antibody panels that the animals produce represent a good diversity of ...

"A few previously reported cases of de novo antibody design have shown only limited success, particularly in terms of target diversity and binding affinity. Our findings prove that AI can reliably ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...